A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With HER2+ AR+ Metastatic or Locally Advanced Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Mar 2019
Price : $35 *
At a glance
- Drugs Enzalutamide (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Astellas Pharma Global Development
- 18 Sep 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 01 Aug 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
- 31 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History